Hyderabad: Bharat Biotech International Limited said on Tuesday that its intranasal COVID-19 iNCOVACC vaccine, which is now available on the CoWIN portal, is priced at Rs 800 (excluding GST) for personal markets and Rs 325 (excluding GST) for government supplies.
A press from the vaccine manufacturer claims that the vaccine will be released in the fourth week of January 2023.
iNCOVACC is the world’s first intranasal COVID vaccine to gain approval for the number one two-dose regimen and heterologous booster dose.
Earlier this month, Bharat Biotech obtained approval from the Central Drug Standards Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC.
Krishna Ella, CEO of BBIL, said: “We evolved Covaxin and iNCOVACC, two COVID vaccines from two other platforms, with two other delivery systems. The intranasal vector delivery platform gives us the ability to expand products, scale them, simple and painless immunization during public fitness emergencies and pandemics. “
Phase III trials of iNCOVACC (as a two-dose regimen) for protection and immunogenicity were conducted in approximately 3100 subjects, at 14 trial sites in India, while heterologous booster dose studies for protection and immunogenicity were conducted in 875 subjects, according to the release. . .
iNCOVACC evolved in partnership with the University of Washington, St. Louis, who had designed and developed the construction of the recombinant adenoviral vector and evaluated its efficacy in preclinical studies, added.